P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS

Míreanna comhchosúla

• Structural Characterization of the Aggregates of Gemtuzumab Ozogamicin
  de réir: Qingping Jiang, et al.
  Foilsithe / Cruthaithe: (2019-04-01)
• Resolution of hypogammaglobulinemia-associated recurrent Campylobacter bacteraemia after hematopoietic cell transplantation (HCT)
  de réir: Emmanouil Karofylakis, MD, et al.
  Foilsithe / Cruthaithe: (2025-02-01)
• Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
  de réir: Giancarlo Fatobene, et al.
  Foilsithe / Cruthaithe: (2021-10-01)
• HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) IN CHILDREN WITH AUTISM SPECTRUM DISORDER: CHALLENGES AND THERAPEUTIC STRATEGIES
  de réir: ASS Ibanez, et al.
  Foilsithe / Cruthaithe: (2024-10-01)
• Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
  de réir: Mahesh Swaminathan, et al.
  Foilsithe / Cruthaithe: (2023-02-01)